Vehicle cream (same formulation of cream as the test product but without active substance) clinical trials
4 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
INCB 18424-319: A phase 3, double-blind, randomised, vehicle-controlled, efficacy and safety study of ruxolitinib cream in participants with Purigo Nodularis. Topical ruxolitinib evaluation in Prurigo Nodularis (TRuE-PN1)
This study is testing a new cream for Prurigo Nodularis, a skin condition causing very itchy bumps. It compares a cream with the active medicine to a plain cream, to see if the new medicine can help reduce itchiness and improve the skin condition over 12 weeks.
For: Prurigo NodularisSpain · Italy · Belgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
INCB 18424-320: A phase 3, double-blind, randomised, vehicle-controlled, efficacy and safety study of ruxolitinib cream in participants with Prurigo Nodularis. Topical ruxolitinib evaluation in Prurigo Nodularis (TRuE-PN2)
This study is testing a new cream for people with very itchy skin lumps called Prurigo Nodularis. It wants to see if the cream, called ruxolitinib, can reduce itching compared to a cream without any medicine in it. The study aims to find out how well it works and if it's safe.
For: Prurigo NodularisAustria · Poland · Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
18424-326: A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
This study is testing a new cream called ruxolitinib for adults with moderate eczema. It aims to see if the cream helps reduce eczema symptoms and itching by comparing it to a cream with no medicine. Researchers will check results after 8 weeks.
For: Atopic DermatitisSpain · Italy · Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema
This study is testing a new cream called ruxolitinib for adults with ongoing hand eczema. It compares the new cream to a dummy cream to see how well it works and if it's safe over 16 weeks, with a longer open-label period.
For: Chronic Hand EczemaGermany · Poland